Plant-Based Vaccines Against Hepatitis B

Pniewski, Tomasz

doi:10.1007/978-1-4939-0850-9_10

Cited by 3 publications

(5 citation statements)

References 122 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For the first time Mason et al ( 1992 ) expressed HBsAg in plants in the form of VLPs. Since then there have been many reports on plant-based production of antigens against hepatitis B using different approaches as summarised by Pniewski ( 2014 ). Few recent reports also show the expression of antigens against hepatitis B.…”

Section: Hepatitismentioning

confidence: 99%

Need of cost-effective vaccines in developing countries: What plant biotechnology can offer?

et al. 2016

View full text Add to dashboard Cite

To treat current infectious diseases, different therapies are used that include drugs or vaccines or both. Currently, the world is facing an increasing problem of drug resistance from many pathogenic microorganisms. In majority of cases, when vaccines are used, formulations consist of live attenuated microorganisms. This poses an additional risk of infection in immunocompromised patients and people suffering from malnutrition in developing countries. Therefore, there is need to improve drug therapy as well as to develop next generation vaccines, in particular against infectious diseases with highest mortality rates. For patients in developing countries, costs related to treatments are one of the major hurdles to reduce the disease burden. In many cases, use of prophylactic vaccines can help to control the incidence of infectious diseases. In the present review, we describe some infectious diseases with high impact on health of people in low and middle income countries. We discuss the prospects of plants as alternative platform for the development of next-generation subunit vaccines that can be a cost-effective source for mass immunization of people in developing countries.

show abstract

Section: Hepatitismentioning

confidence: 99%

Need of cost-effective vaccines in developing countries: What plant biotechnology can offer?

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Among oral vaccines, the one against HBV (Hepatitis B Virus) has been a key example. During the past decades, the concept of an anti-HBV vaccine evolved from raw tissues used as ‘edible’ vaccines to orally administered derivatives obtained from converted plant tissue (Pniewski 2014). Recently, great progress has been made in the expression of all HBV surface antigens: small S-, medium M- and large L-HBsAg in donor plants, as well as in technologies for their conversion into immunogenic, highly condensed and durable formulations.…”

Section: Introductionmentioning

confidence: 99%

Micropropagation of transgenic lettuce containing HBsAg as a method of mass-scale production of standardised plant material for biofarming purposes

et al. 2016

Self Cite

View full text Add to dashboard Cite

Key message Micropropagation protocol of transgenic lettuce bearing S-, M- and L-HBsAg was developed for increased production of uniformised material for oral vaccine preparation. AbstractEffective manufacturing of plant-based biopharmaceuticals, including oral vaccines, depends on sufficient content of a protein of interest in the initial material and its efficient conversion into an administrable formulation. However, stable production of plants with a uniformised antigen content is equally important for reproducible processing. This can be provided by micropropagation techniques. Here, we present a protocol for micropropagation of transgenic lettuce lines bearing HBV surface antigens: S-, M- and L-HBsAg. These were multiplied through axillary buds to avoid the risk of somaclonal variation. Micropropagation effectiveness reached 3.5–5.7 per passage, which implies potential production of up to 6600 plant clones within a maximum 5 months. Multiplication and rooting rates were statistically homogenous for most transgenic and control plants. For most lines, more than 90 % of clones obtained via in vitro micropropagation had HBsAg content as high as reference plants directly developed from seeds. Clones were also several times more uniform in HBsAg expression. Variation coefficients of HBsAg content did not exceed 10 % for approximately 40–85 % of clones, or reached a maximum 20 % for 90 % of all clones. Tissue culture did not affect total and leaf biomass yields. Seed production for clones was decreased insignificantly and did not impact progeny condition. Micropropagation facilitates a substantial increase in the production of lettuce plants with high and considerably equalised HBsAg contents. This, together with the previously reported optimisation of plant tissue processing and its long-term stability, constitutes a successive step in manufacturing of a standardised anti-HBV oral vaccine of reliable efficacy.

show abstract

“…After dialysis, caesium concentration dropped to 0.7 µg/ml as assayed by ICP MS. Final content of S- and M-HBsAg amounted 1.693 and 0.727 µg/ml, respectively, in comparison to 0.1–0.7 µg/ml achieved previously using sucrose gradient (Pniewski 2014 ), and then was approximately fivefold concentrated using Amicon ® Ultra filtration columns (Millipore).…”

mentioning

confidence: 69%

“…Here, the responses were induced by several times lower antigen doses (0.1–0.3 µg) and without special enforcement (e.g. Freund’s adjuvant or boosting with a commercial vaccine), but they gave results comparable or higher than reported previously (see Pniewski 2014 for review). We also showed—for the first time—that parenterally delivered plant-derived M-HBsAg triggered also specific anti-preS2 antibodies.…”

mentioning

confidence: 74%

“…Among the most advanced plant-derived biopharmaceuticals, glucocerebrosidase for the treatment of Gaucher disease produced in carrot cells (Protalix™) has been already approved by FDA, while quadrivalent influenza vaccine produced by Medicago Inc. in Nicotiana benthamiana via viral vector-mediated expression, has been enrolled in phase II of clinical trials (Ward et al 2014 ). Also HBV antigens, mostly S-HBsAg, were effectively produced in plants and their immunogenicity was proved, both after oral or parenteral administration (Pniewski 2014 ). Yet in those studies, almost exclusively the titre of anti-HBs antibodies as the most general response to HBV antigens, was analysed.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Immunogenicity of parenterally delivered plant-derived small and medium surface antigens of hepatitis B virus

et al. 2016

Self Cite

View full text Add to dashboard Cite

Key messageIntramuscularly delivered plant-derived M-HBsAg was compared to S-HBsAg, and as a result elicited specific anti-preS2 antibodies and significantly higher titre of anti-HBs antibodies, together with IgG isotype profile indicating some Th1 polarisation, apart from the main Th2 response.AbstractHBV prevalence is still threatening, regardless of prevention programmes using vaccines containing S-HBsAg, supplemented by third-generation vaccines, comprising also M- and L-HBsAg. Plant expression systems offer a cost-effective production option of the antigens. Plant-derived S- and M-HBsAg, intramuscularly delivered to mice, elicited anti-HBs antibodies several times higher than high responsiveness threshold titre. M-HBsAg induced stronger response of anti-HBs and also specific anti-preS2 antibodies. IgG isotype profiles indicated mainly Th2 response, yet Th1 polarisation was also pointed out, in some larger extent for M-HBsAg. These results correspond to research on CHO-derived M-HBsAg vs. commercial vaccines based on S-HBsAg and support potency of plant-derived antigens as alternative injection vaccines.

show abstract

Plant-Based Vaccines Against Hepatitis B

Cited by 3 publications

References 122 publications

Need of cost-effective vaccines in developing countries: What plant biotechnology can offer?

Need of cost-effective vaccines in developing countries: What plant biotechnology can offer?

Micropropagation of transgenic lettuce containing HBsAg as a method of mass-scale production of standardised plant material for biofarming purposes

Immunogenicity of parenterally delivered plant-derived small and medium surface antigens of hepatitis B virus

Contact Info

Product

Resources

About